Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Neuroone Medical Technologies (NMTC) Accumulated Depreciation & Amortization (2020 - 2025)

Neuroone Medical Technologies (NMTC) has disclosed Accumulated Depreciation & Amortization for 5 consecutive years, with $798823.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Accumulated Depreciation & Amortization rose 42.78% year-over-year to $798823.0, compared with a TTM value of $798823.0 through Sep 2025, up 42.78%, and an annual FY2025 reading of $798823.0, up 42.78% over the prior year.
  • Accumulated Depreciation & Amortization was $798823.0 for Q3 2025 at Neuroone Medical Technologies, up from $679063.0 in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $540.0 billion in Q3 2022 and bottomed at $73268.0 in Q2 2021.
  • Average Accumulated Depreciation & Amortization over 5 years is $38.6 billion, with a median of $294991.0 recorded in 2023.
  • The sharpest move saw Accumulated Depreciation & Amortization soared 599604180.19% in 2022, then crashed 100.0% in 2023.
  • Year by year, Accumulated Depreciation & Amortization stood at $109634.0 in 2021, then surged by 97.63% to $216667.0 in 2022, then skyrocketed by 54.61% to $334984.0 in 2023, then skyrocketed by 84.79% to $619008.0 in 2024, then grew by 29.05% to $798823.0 in 2025.
  • Business Quant data shows Accumulated Depreciation & Amortization for NMTC at $798823.0 in Q3 2025, $679063.0 in Q1 2025, and $619008.0 in Q4 2024.